J. Sanderson

Azathioprine is effective for oral involvement in Crohn's disease but not for orofacial granulomatosis alone.

J. Sanderson, A. Mentzer, S. Challacombe, 2016, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors

M. Parkes, J. Sanderson, J. Reynolds, 2017, Alimentary pharmacology & therapeutics.

Utilisation of anti-TNF levels in a UK tertiary IBD centre

J. Digby-Bell, Z. Arkir, S. Anderson, 2016, Frontline Gastroenterology.

An audit of adherence to anti-tnf therapy in patients with inflammatory bowel disease

J. Sanderson, J. Baker, M. Sastrillo, 2011, Gut.

Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitis

J. Sanderson, L. Boursier, J. Spencer, 2002, Gut.

Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease

Graham M Lord, J. Sanderson, S. Yagel, 2015, Gut.